NextCell Pharma AB to present at several events in next 2 weeks
NextCell Pharma AB (”NextCell”) informs that during the next two weeks there is ample opportunities for (potential) investors to attend presentations given by and conduct discussions with NextCell Pharma personnel.
Sessions where NextCell Pharma representatives will be present:
- Aktiespararna Södertälje – September 4th 18:30-21:00
- Advanced Medicinal Therapy Products – A game changer in medicine? – Malmoe, September 12th 13:00-17:00
- Nordic Life Science days, Malmoe – September 12th – 14th
- Aktiespararna Burlöv – September 13th 19:00-21:00
During these meetings NextCell will provide the audience with an overview of its current activities and its view of the future. Besides the company itself, both the drug candidate Protrans™ and its stem cell family saving bank Cellavivia™ will be discussed. After the presentations, there will be ample opportunity to engage with the NextCell team.
Stay up to date with the latest development in NextCell Pharma
Linkedin: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
Instagram: https://www.instagram.com/nextcellpharma/
For more information about NextCell Pharma AB, please contact:
Mathias Svahn, CEO
Phone: 0702-615 504
E-mail: mathias.svahn@nextcellpharma.com
About NextCell Pharma AB:
Stem cells are expected to change the way how many of today's life-threatening diseases are treated. NextCell
Pharma AB develops ProTrans™, a drug candidate consisting of stem cells for the primary treatment of autoimmuneand inflammatory diseases as well as for use in kidney transplants. ProTrans™ consists of selected stem cells derived from the umbilical cord tissue with NextCell Pharma AB's proprietary method. In addition, the company has a service called Cellaviva, Sweden's first and only IVO-approved stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue.